5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia
Vicki L. Ellingrod, PharmD, BCPP, Brian C. Lund, PharmD, MS, BCPP, Paul J. Perry, PhD, BCPP, Kristy Bever-Stille, PharmD, BCPP, Frank Fleming, BSN, Timothy L. Holman, MA, and Del Miller, PharmD, MD